NSRX – nasus pharma ltd. ordinary shares (US:AMEX)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

NSRX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

1/20

08:00 am

nsrx

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

High Report

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Report

12/22

08:00 am

nsrx

Nasus Pharma CEO Issues 2025 Letter to Shareholders

Medium Report

Nasus Pharma CEO Issues 2025 Letter to Shareholders

Report

11/20

08:15 am

nsrx

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Neutral Report

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Report

11/18

08:42 am

nsrx

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed [Yahoo! Finance]

Medium Report

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed [Yahoo! Finance]

Report

11/18

08:00 am

nsrx

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Medium Report

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.